Page last updated: 2024-12-08
tempace
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
tempace: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 518988 |
| CHEBI ID | 180673 |
| MeSH ID | M0272976 |
Synonyms (28)
| Synonym |
|---|
| CHEBI:180673 |
| 4-acetamido-2,2,6,6-tetramethylpiperidine-1-oxyl |
| 2,2,6,6-tetramethyl-4-acetamidopiperidine-1-oxyl |
| 4-acetamido-2,2,6,6-tetramethylpiperidinyloxyl |
| 4-acetamido-tempo, free radical, 97% |
| tempace |
| 4-acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl |
| FT-0653861 |
| unii-g7abj73l6s |
| (4-acetamido-2,2,6,6-tetramethyl-1-piperidinyl)oxidanyl |
| ec 423-840-3 |
| g7abj73l6s , |
| AKOS015910523 |
| 4-acetamido-tempo, free radical |
| W-201301 |
| 4-acetylamino-tempo |
| 2,2,6,6-tetramethyl-4-acetamidopiperidin-1-oxyl |
| 4-acetamide-2,2,6,6-tetramethyl-1-piperidin-yloxy |
| 4-n-acetylamino-tempo |
| piperidinooxy, 4-acetamido-2,2,6,6-tetramethyl- |
| 4-acetamino-2,2,6,6-tetramethylpiperidine-1-oxyl |
| mfcd00043593 |
| 4-acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl, purum, >=98.0% (hplc) |
| CS-0188148 |
| 4-acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl free radical [catalyst for oxidation] |
| DTXSID60932959 |
| AS-17419 |
| 4-acetamido-2,2,6,6-tetramethylpiperidine1-oxyl |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The results clearly confirmed that the toxic effect could result either from the presence or structure of substituent(s) at position 4 of the free radical piperidine moiety." | ( Tempicol-3, a novel piperidine-N-oxide stable radical and antioxidant, with low toxicity acts as apoptosis inducer and cell proliferation modifier of Yoshida Sarcoma cells in vivo. Gwoździnski, K; Głebska, J; Jóźwiak, Z; Koceva-Chyła, A; Kochman, A; Metodiewa, D, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (2)
| Role | Description |
|---|---|
| radical scavenger | A role played by a substance that can react readily with, and thereby eliminate, radicals. |
| radiation protective agent | Any compound that is able to protect normal cells from the damage caused by radiation therapy. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (3)
| Class | Description |
|---|---|
| aminoxyls | Radicals derived from hydroxylamines by removal of the hydrogen atom from the hydroxy group. The synonymous terms nitroxyl radicals and nitroxides erroneously suggest the presence of a nitro group. |
| piperidinecarboxamide | |
| secondary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (3)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 24.10
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.10) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||